• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

舒必利与亚硝酸盐反应形成的N-亚硝基化合物的致突变性;半胱氨酸及其衍生物的影响。

Mutagenicity of N-nitroso compounds formed by the reaction of sulpyrine with nitrite; effects of cysteine and its derivatives.

作者信息

Sakai A, Tanimura A

出版信息

IARC Sci Publ. 1982(41):709-17.

PMID:6982852
Abstract

Cysteine and its derivatives were tested for their effect on the mutagenic activities of nitrosation products of sulpyrine, 1-diketo-butyryl-1-phenyl-2-methyl-2-nitrosohydrazide hydrate (DPMN) and 4-(N-methyl-N-nitroso)aminoantipyrine (MNAA), using Salmonella typhimurium TA100. The addition of cysteine, cysteamine, cysteine methyl ester, glutathione, 2-mercaptoethanol and homocysteine to the mixture of DPMN and bacteria before pre-incubation markedly increased the mutagenic activity of DPMN in the absence of rat-liver microsomal preparation (S9 mix). An approximately thirty-fold increase in the number of revertants was caused by the addition of cysteine at a concentration of 3 mmol/1. Studies of the structure-activity relationship suggest that a thiol group is necessary in order that the compounds exhibit the enhancing effect and that the thiol compounds having an amino group at the beta-position are more active than the others. Both cysteine and glutathione were rather inhibitory in the development of mutagenesis by MNAA in the presence of S9 mix.

摘要

使用鼠伤寒沙门氏菌TA100,检测了半胱氨酸及其衍生物对舒林酸、1,2-二酮丁酰-1-苯基-2-甲基-2-亚硝基酰肼水合物(DPMN)和4-(N-甲基-N-亚硝基)氨基安替比林(MNAA)亚硝化产物致突变活性的影响。在预孵育前,向DPMN与细菌的混合物中添加半胱氨酸、半胱胺、半胱氨酸甲酯、谷胱甘肽、2-巯基乙醇和高半胱氨酸,在没有大鼠肝微粒体制剂(S9混合物)的情况下,显著增加了DPMN的致突变活性。添加浓度为3 mmol/L的半胱氨酸可使回复突变体数量增加约30倍。结构-活性关系研究表明,化合物要表现出增强作用,巯基是必需的,且在β位具有氨基的巯基化合物比其他化合物更具活性。在S9混合物存在的情况下,半胱氨酸和谷胱甘肽对MNAA诱导的诱变作用均有相当程度的抑制。

相似文献

1
Mutagenicity of N-nitroso compounds formed by the reaction of sulpyrine with nitrite; effects of cysteine and its derivatives.舒必利与亚硝酸盐反应形成的N-亚硝基化合物的致突变性;半胱氨酸及其衍生物的影响。
IARC Sci Publ. 1982(41):709-17.
2
Mutagenicity of reaction products of sulpyrine with nitrite.安乃近与亚硝酸盐反应产物的致突变性。
Mutat Res. 1981 Sep;90(1):57-65. doi: 10.1016/0165-1218(81)90050-1.
3
Mutagenicity studies in Salmonella typhimurium on some carcinogenic N-nitramines in vitro and in the host-mediated assay in rats.鼠伤寒沙门氏菌对某些致癌性N-亚硝胺的体外致突变性研究以及在大鼠体内宿主介导试验中的研究。
Cancer Res. 1981 Aug;41(8):3205-10.
4
Salmonella/human S9 mutagenicity test: a collaborative study with 58 compounds.沙门氏菌/人源S9致突变性试验:58种化合物的协作研究
Mutagenesis. 2005 May;20(3):217-28. doi: 10.1093/mutage/gei029. Epub 2005 Apr 20.
5
Chemistry and mutagenicity of alpha-hydroxy nitrosamines.α-羟基亚硝胺的化学性质与致突变性。
IARC Sci Publ. 1982(41):553-9.
6
Mutagenicity of 4-aminoantipyrine and 4-nitrosoantipyrine, the C-nitroso derivative of antipyrine.
Mutat Res. 1988 Nov;206(3):317-26. doi: 10.1016/0165-1218(88)90117-6.
7
NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.国家毒理学计划关于水合氯醛(化学物质登记号:302-17-0)毒性和代谢研究的技术报告。通过灌胃法给予F344/N大鼠和B6C3F1小鼠。
Toxic Rep Ser. 1999 Aug(59):1-66, A1-E7.
8
NTP Technical Report on the comparative toxicity studies of allyl acetate (CAS No. 591-87-7), allyl alcohol (CAS No. 107-18-6) and acrolein (CAS No. 107-02-8) administered by gavage to F344/N rats and B6C3F1 mice.NTP关于经口给予F344/N大鼠和B6C3F1小鼠乙酸烯丙酯(CAS编号:591-87-7)、烯丙醇(CAS编号:107-18-6)和丙烯醛(CAS编号:107-02-8)的比较毒性研究技术报告。
Toxic Rep Ser. 2006 Jul(48):1-73, A1-H10.
9
Differential mutagenicity of reaction products of various pyrazolones with nitrite.各种吡唑啉酮与亚硝酸盐反应产物的差异诱变性。
Mutat Res. 1978 Jul;57(3):287-96. doi: 10.1016/0027-5107(78)90213-0.
10
[Mutagenicity of sulpyrine and the metabolites].[安乃近及其代谢产物的致突变性]
Nichidai Koko Kagaku. 1986 Jun;12(2):119-31.